nach oben

Breast Cancer Research

Erschienen in:

01.05.2008 | Poster presentation

Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation

verfasst von: T Stein, E Cosimo, P Smith, R Simon, K Price, L Baird, AK Bell, G Sauter, T Crook, BA Gusterson

Erschienen in: Breast Cancer Research | Sonderheft 2/2008

Einloggen, um Zugang zu erhalten

Excerpt

Reelin is a secreted signalling protein whose major function has so far been described in the developing brain, where it is involved in cell positioning of neuronal progenitor cells. Recently, the Reelin promoter has been found to be methylated in pancreatic cancer and this was associated with increased migratory ability [1], whereas in the prostate Reelin expression is associated with high-grade cancers [2]. …

Sato N, Fukushima N, Chang R, et al: Differential and epigenetic gene expression profiling identifies frequent disruption of the RELN pathway in pancreatic cancers. Gastroenterology. 2006, 130: 548-565. 10.1053/j.gastro.2005.11.008.CrossRefPubMed

Perrone G, Vincenzi B, Zagami M, et al: Reelin expression in human prostate cancer: a marker of tumor aggressiveness based on correlation with grade. Mod Pathol. 2007, 20: 344-351. 10.1038/modpathol.3800743.CrossRefPubMed

Titel: Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation
verfasst von: T Stein
E Cosimo
P Smith
R Simon
K Price
L Baird
AK Bell
G Sauter
T Crook
BA Gusterson
Publikationsdatum: 01.05.2008
Verlag: BioMed Central
Erschienen in: Breast Cancer Research / Ausgabe Sonderheft 2/2008
Elektronische ISSN: 1465-542X
DOI: https://doi.org/10.1186/bcr1909

Neu im Fachgebiet Onkologie

25.04.2024 | Nierenkarzinom | Nachrichten

Springer Medizin

Reelin expression in breast tumours is associated with increased survival and is controlled by promoter methylation

Excerpt

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie

Springer Medizin

Excerpt

Bitte loggen Sie sich ein, um Zugang zu diesem Inhalt zu erhalten

Weitere Artikel der Sonderheft 2/2008

Mechanisms of apoptosis and cell-cycle arrest in subcutaneous breast tumours treated sequentially with doxorubicin followed by zoledronic acid

Matrix metalloproteinase-8 is a regulator of the clinical aggressiveness of mammary tumours

Cellular localization of the proto-oncogenic p53 inhibitor AGR2 protein in breast cancer

Molecular diversity of human breast cancer: clinical and therapeutic implications

Identification and role of migration stimulating factor isoforms in breast carcinomas

Inhibitor of apoptosis proteins as a therapeutic target in breast cancer

Neu im Fachgebiet Onkologie

Adjuvante Immuntherapie verlängert Leben bei RCC

Alectinib verbessert krankheitsfreies Überleben bei ALK-positivem NSCLC

Bei Senioren mit Prostatakarzinom auf Anämie achten!

ICI-Therapie in der Schwangerschaft wird gut toleriert

Update Onkologie